LPCN – lipocine inc. (US:NASDAQ)

News

Lipocine (LPCN) was upgraded by Wall Street Zen from "sell" to "hold"
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Lipocine (NASDAQ:LPCN) was upgraded by analysts at Wall Street Zen f
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com